Welcome Address

Dear Colleagues,

On behalf of the Royal Belgian Society of Rheumatology (KBVR-SRBR), we are pleased to announce the first-ever online edition of the Belgian Congress on Rheumatology.

This virtual congress will take place on Friday 19 March 2021.

Much to our regret it will not be possible to meet in person, but we are happy to be able to propose an interesting online programme consisting of invited talks, oral presentations and Updates in Therapeutics.

In addition to the scientific programme, a virtual exhibition and poster area will be available. There will be ample time for visiting the virtual booths, the online posters and for networking.

Together with the KBVR-SRBR board members, we hope to welcome many of you to the first virtual edition of the Belgian Congress on Rheumatology and remain,

Yours faithfully,

Peggy Jacques
Scientific President
Morning Programme

08.45 Welcome and Opening Ceremony
Valérie Badot, President KBVR-SRBR
Catherine Bailleux, Association Manager &
Jorien Geukens, Office & Project Assistant, KBVR-SRBR
Peggy Jacques, Scientific Organiser

09.10 FWRO/FRSR Award Ceremony
René Westhovens (KUL)

Morning Programme – Part I
Chairs: Laurent Méric de Bellefon (CNDG, CHU Saint-Pierre Brussels, UCL) & Patrick Verschueren (KUL)

09.20 Keynote Lecture
From clinical trials to clinical practice: A good match?
Josef Smolen (Austria)

Young Investigators’ Meeting – Part I

09.45 Axial involvement in early peripheral spondyloarthritis: A prospective MRI study
Thomas Renson (UGent, VIB)

09.55 Immunoglobulin G antibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts
Pieter Ruytinx (UHasselt)

10.05 Interleukin-23 inhibitors and their apparent ineffectiveness in the treatment of axial spondyloarthritis: A systematic review with meta-analysis
Louise Vanhoutte (KUL)

10.15 Synovial tissue histopathology findings in early RA – Is it useful?
Analysis of the Belgian CAP48 cohort
Stéphanie de Montjoye (UCL, IREC)

10.25 Update in Therapeutics – Organised with an educational grant from AbbVie
The importance of achieving remission in RA
René Marc Flipo (France)

Morning Programme

10.40 Update in Therapeutics – Organised with an educational grant from UCB
Uveitis in axSpA
Irene van der Horst (The Netherlands)

10.55 Coffee break and Visit of the Exhibition

Morning Programme – Part II
Chairs: Yves Piette (UGent, AZ Sint-Jan Brugge) & Olivier Malaise (ULg)

Abstract Presentations

11.20 Long-term effectiveness of methotrexate with step down glucocorticoids (COBRA Slim) versus other conventional DMARD regimens as initial RA therapy: 5-year outcomes of the CareRA trial
Veerle Stouten (KUL)

11.30 Spinal magnetic resonance imaging lesions in healthy subjects compared to axial spondyloarthritis patients
Manouk de Hooge (UGent, VIB)

11.40 Should we use bioDMARDs in first intention in early Rheumatoid Arthritis? Results at 5 years from the ERA Louvain Brussels cohort
Emilie Sapart (UCL)

11.50 Patients with early rheumatoid arthritis considered to have a favourable risk profile and treated according to a step-up strategy have an increased risk of chronic analgesic consumption
Sofia Pazmino (KUL)

12.00 Novel autoantibody biomarkers for the prediction of response to first-line combination therapy in rheumatoid arthritis
Patrick Vandormael (UHasselt)

12.10 Interplay between Treg and iNKT cells reveals a marked tissue tropism of immune regulatory networks in combined gut and joint inflammation
Koen Venken (VIB, UGent)
**Afternoon Programme**

**Afternoon Programme - Part I**  
Chairs: Barbara Neerinckx (KUL) & Filip Van den Bosch (UGent)

**Young Investigators’ Meeting - Part II**

14.00  
Laser Speckle Contrast Analysis (LASCA) in rheumatoid arthritis  
Michaël Vanden Bulcke (UGent)

14.10  
The FLARE-RA questionnaire can identify OMERACT flares in patients with rheumatoid arthritis included in the TapERA trial  
Delphine Bertrand (KUL)

14.20  
May capillaroscopy be a candidate tool in future algorithms for SSc-ILD: Are we looking for the holy grail? A systematic review  
Amber Vanhaecke (UGent)

14.30  
Epitope mapping of MDA5 using patient plasma derived autoantibodies  
Eveline Van Gompel (Karolinska Institute, KUL)

14.40  
Update in Therapeutics – Organised with an educational grant from Galapagos  
Evolution of a JAK inhibitor: From bench to bedside  
Peter Taylor (UK)

14.55  
Update in Therapeutics – Organised with an educational grant from Celltrion  
Novel opportunities with Infliximab in rheumatic diseases  
René Westhovens (KUL)

15.10  
Update in Therapeutics – Organised with an educational grant from Roche  
Current and future treatments for GCA  
Daniel Blockmans (KUL)

15.25  
Coffee Break and Visit of the Exhibition

---

**Morning Programme**

12.20  
Update in Therapeutics – Organised with an educational grant from Sanofi  
Update on RA and Diabetes  
Philip Remans (Reumacentrum Genk)

Thieves Market

12.35  
Hydroxychloroquine use not so harmless: Little reminder from a clinical case  
Tracy Vandergraes (ULB)

12.45  
Treating cancer and associated “paraneoplastic” dermatomyositis with immune checkpoint inhibitor, a false good idea?  
Florane Chauveheid (ULg)

12.55  
Clinical case: Systemic lupus erythematosus mimicry after viral infection with Coxsackie B4  
Julie Terrasson (KUL)

13.05  
Lunch Break, Visit of the Exhibition and Poster Viewing
Afternoon Programme

Afternoon Programme - Part II
Chairs: Pascale Volders (ReumaClinic Genk) & Adrien Nzeusseu (UCL)

15.45 Year in review - Clinical and Basic Science
Gaelle Varkas (UGent) and Eric Gracey (VIB, UGent)

Abstract Presentations

16.15 Incidence and prevalence of systemic sclerosis associated interstitial lung disease in Flanders: A 12-years multicentre prospective cohort study
Vanessa Smith (UGent)

16.25 Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
Farah Tamirou (UCL)

16.35 Serum IgG-undergalactosylation profiles reflect cumulative exposure to systemic inflammation in spondyloarthritis patients
Ann-Sophie De Craemer (UGent, VIB)

16.45 The use of disease activity indicators for rheumatoid arthritis in Belgian daily clinical practice
Emma Buckinx (KUL)

16.55 Unmasking the role of salivary gland involvement in anti-SSA positive patients
Liselotte Deroo (UGent)

17.05 Systematic analysis of Covid-19 infections and symptoms in systemic lupus erythematosus population: Correlation with disease severity and treatments
Olivier Malaise (ULg)

17.15 Keynote Lecture
Infection prevention and vaccination strategies
Charlotte Martin (CHU St Pierre)

17.40 Announcement of the winners of today’s questionnaire in support of Be-R-Connected
Catherine Bailleux, Association Manager & Jorien Geukens, Office & Project Assistant, KBVR-SRBR

17.45 Closure of the Congress and Visit of the Exhibition
Valérie Badot, President KBVR-SRBR
<table>
<thead>
<tr>
<th></th>
<th>ePoster List</th>
</tr>
</thead>
</table>
| **01** | Axial involvement in early peripheral spondyloarthritis: A prospective MRI study  
Thomas Renson (UGent, VIB) |
| **02** | Immunoglobulin G antibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts
Pieter Ruytinx (UHasselt) |
| **03** | Interleukin-23 inhibitors and their apparent ineffectiveness in the treatment of axial spondyloarthritis: A systematic review with metaanalysis
Louise Vanhoutte (KUL) |
| **04** | Synovial tissue histopathology findings in early RA – Is it useful?  
Analysis of the Belgian CAP48 cohort
Stéphanie de Montjoye (UCL, IREC) |
| **05** | Laser Speckle Contrast Analysis (LASCA) in rheumatoid arthritis
Michaël Vanden Bulcke (UGent) |
| **06** | The FLARE-RA questionnaire can identify OMERACT flares in patients with rheumatoid arthritis included in the TapERA trial
Delphine Bertrand (KUL) |
| **07** | May capillaroscopy be a candidate tool in future algorithms for SSCILD: Are we looking for the holy grail? A systematic review
Amber Vanhaecke (Ugent) |
| **08** | Epitope mapping of MDA5 using patient plasma derived autoantibodies
Eveline Van Gompel (Karolinska Institute, KUL) |
| **09** | Ultrasound as a diagnostic tool in giant cell arteritis - Experience from a Brussels hospital
Ioannis Raftakis (ULB) |
| **10** | Nailfold videocapillaroscopy: A diagnostic tool when clinical evaluation is misleading
Yora Mostmans (ULB) |
| **11** | Influence of extra-articular damage on use of biotherapies in patients with spondyloarthritis: A retrospective study
Naïla Senhaji (ULB) |
| **12** | Remission in axial spondyloarthritis: Is there a difference between NSAIDs and biologics in the real life?
Charlotte Baert (UCL) |
| **13** | Ixekizumab significantly improves patient-reported overall health as measured by SF-36 in patients with active ankylosing spondylitis/radiographic axial spondyloarthritis: 52-week results of two phase 3 trials
Filip Van den Bosch (UGent) |
| **14** | Patient-reported outcomes from a randomised, open-label, parallel-group study evaluating ixekizumab versus adalimumab in patients with PsA who are biologic DMARD naive: 24-week results
Filip Van den Bosch (UGent) |
| **15** | Are axial spondyloarthritis patients diagnosed differently in an academic versus peripheral hospitals?
Ann-Sophie De Craemer (UGent) |
| **16** | Minimal radiographic damage of sacroiliac joints detected in psoriatic arthritis patients
Manouk de Hooge (UGent) |
| **17** | Prevalence of clinical symptoms and laboratory markers in idiopathic inflammatory myopathies
Emilie De Maertelaere (UGent) |
| **18** | SpA during the COVID-19 pandemic – Influence on patients’ health perception
Sophie De Mits (UGent) |
| **19** | SpA during the COVID-19 pandemic – Chest expansion is the most affected clinical measurement
Sophie De Mits (UGent) |
| **20** | Secukinumab improves clinical and imaging outcomes in patients with Psoriatic Arthritis and axial manifestations with inadequate response to NSAIDs: Week 52 results from the MAXIMISE trial
Joëlle Margaux (ULB) |
| P13 | Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study  
Filip Van den Bosch (UGent) |
| P14 | Plasmocytosis and nephrotic syndrome revealing Sjögren’s Syndrome  
Céline La (ULB) |
| P15 | Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment  
Joris Lenaerts (KUL) |
| P16 | Nailfold capillaroscopy in Sjögren’s Syndrome: A systematic literature review and standardised interpretation  
Karin Melsens (UGent) |
| P17 | Magnetic resonance imaging of the sacroiliac joints in healthy subjects: Occurrence of inflammatory and structural lesions in relation to age  
Thomas Renson (UGent) |
| P18 | Screening for immunoglobulin A antibody reactivity in early axial spondyloarthritis identifies novel antigenic targets  
Pieter Ruytinx (UHasselt) |
| P19 | Fatigue and vitality but not disease outcomes strongly predict sensor-based physical activity behaviour in patients with axial spondyloarthritis  
Marlies Kaerts (KUL) |
| P20 | Real-world efficacy and safety of Apremilast in Belgian patients with psoriatic arthritis: Final analysis of the multicentre, prospective APOLO study  
Kurt De Vlam (KUL) |
| P21 | The impact of persistent inflammatory changes on prevalence of fat lesions in patients with axial spondyloarthritis treated with certolizumab pegol: 4-year MRI results from RAPID-axSpA  
Adrien Nzeusseu (UCL) |
| P22 | Rheumatoid arthritis, Merkel cell carcinoma and checkpoints inhibitors: A case report  
Elena-Raluca Dragan (ULB) |
| P23 | Reduction of complement serum levels in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibodies  
Tracy Vandergraesen (ULB) |
| P24 | Otitis media as the presenting symptom in a patient with granulomatosis and vasculitis  
Ioannis Raftakis (ULB) |
| P25 | Auto-immune or paraneoplastic myositis? A case report  
Carole Nagant (ULB) |
| P26 | Pre-exposure prophylaxis with hydroxychloroquine does not prevent acquisition of SARS-CoV-2  
Héloïse Van Noten (ULB) |
| P27 | The total FLARE-RA score is associated with flares three months later in patients with rheumatoid arthritis participating in the TapERA trial  
Delphine Bertrand (KUL) |
| P28 | Barriers and facilitating factors of nurse led clinics for patients with rheumatoid arthritis  
Diederik De Cock (KUL) |
| P29 | The ideal mhealth application for rheumatoid arthritis: Qualitative findings from stakeholder focus groups  
Diederik De Cock (KUL) |
| P30 | The choice of bDMARD or tsDMARD therapy as first line therapy: Data of the TARDIS-RA registry, a nationwide Belgian biologic registry  
Diederik De Cock (KUL) |
| P31 | A window of opportunity to lower fatigue complaints in patients with early rheumatoid arthritis: Data from the CareRA trial  
Diederik De Cock (KUL) |
ePoster List

P32 Prospective non-interventional study to evaluate the use of glucocorticoids in combination with tocilizumab in patients with rheumatoid arthritis in Belgium: COGNOS
Marie-Joëlle Kaiser (ULiège)

P33 Delayed recognition of lung involvement in Antisynthetase syndrome after seronegative polyarthritis onset: A case report
Elke Decommer (VUB)

P34 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: An updated integrated safety analysis
Patrick Durez (UCL)

P35 Herpes zoster infections in patients with inflammatory arthritis
Hannah Claus (UGent)

P36 An unusual case of horizontal fracture of the lower endplate in a man with diffuse idiopathic skeletal hyperostosis
Abeline Kapuczinski (ULB)

P37 An unusual case of spondylodiscitis and infectious sacroiliitis due to Listeria monocytogenes
Abeline Kapuczinski (ULB)

P38 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 52-week results
René Westhovens (KUL)

P39 Efficacy and safety of filgotinib in methotrexate-naïve patients with RA: FINCH3 52-week results
René Westhovens (KUL)

P40 Integrated safety analysis of filgotinib treatment for RA from seven clinical trials
Patrick Durez (UCL)

P41 ReumaWerkt: Promoting professional reintegration of people with RMDs
Anja Marchal (ReumaNet)

P42 Survey on the consultation profile of rheumatologists in Wallonia and Brussels for inflammatory joint diseases
Laurent Meric de Bellefon (UCL) - On Behalf of the Professional Association of Rheumatologists

P43 Clinical treatment response still does not match patient reported improvement, even in early rheumatoid arthritis
Sofia Pazmino (KUL)

P44 Granulomatosis with polyangiitis overlapping IgG4-related disease?
Aureliano Pistone (ULB)

P45 Clinical course of COVID-19 infection in inflammatory rheumatologic patients: A monocentric Belgian experience
Aureliano Pistone (ULB)

P46 A heterozygous mutation M694V in the MEFV gene and HLAB27 negative spondioarthritis: The chicken egg paradox?
Julie Sarrand (ULB)

P47 Should we use glucocorticoid in early rheumatoid arthritis? Results at 5 years from the ERA Louvain Brussels cohort
Emilie Sapart (UCL)

P48 Ultrasound as an imaging biomarker of early response to tocilizumab and methotrexate in very early rheumatoid arthritis, TOVERA – A longitudinal study
Maria Stoenoiu (UCL)

P49 Complete thoracolumbar spinal cord injury after minimal trauma in a patient with long-standing ankylosing spondylitis
Eugénie Van Mieghem (UA)

P50 The use of mycophenolate in the treatment of corticosteroid resistant eosinophilic fasciitis - A case report
Steven Van Offel (UA)

P51 Clinical case: Avascular necrosis of the foot and ankle in a patient with systemic sclerosis
Helène Wastyn (KUL)

P52 Preliminary results of the Be-MULTRA study: Sonographic response to treatment with methotrexate in early rheumatoid arthritis
Ruth Wittoek (UGent)
### Registration

#### Registration Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
<th>Until</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members KBVR-SRBR</td>
<td>€ 75,00</td>
<td>18 March</td>
</tr>
<tr>
<td>Non Members</td>
<td>€ 95,00</td>
<td></td>
</tr>
<tr>
<td>Emeritus</td>
<td>€ 25,00</td>
<td></td>
</tr>
<tr>
<td>Trainees in Rheumatology*</td>
<td>€ 25,00</td>
<td></td>
</tr>
</tbody>
</table>

* Registration as a trainee or researcher non-MD will only be accepted if accompanied by a copy of your student card or a certificate of your director (proof to be uploaded during the registration process). Without proof the non-member fee will be charged.

### The registration fee for participants includes

- Participation in all scientific sessions
- Participation in the ‘Updates in Therapeutics’ organised by the Industry
- Access to the virtual exhibition and ePosters
- Networking opportunities on the online platform

### How to register

You can register online through the congress website www.rheumacongress.be. Click on ‘Registration’ for details and access to the online registration form. When your registration is completed successfully, you will receive an automatic confirmation. You can also print an invoice when you finalise your online registration.

### Changes/Name Substitutions

You will receive a personal link in your final confirmation email. With this link it will be possible to make changes or transfer your registration to a colleague free of charge.

### Cancellations

Participants canceling their registration before 1 March 2021, will receive a 50% refund. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing to the Organising Secretariat. All refunds will be processed after the Congress.